The pharmaceutical industry is buzzing with news of the withdrawal of the proposed HHS rule to eliminate drug rebates in Medicare and Medicaid plans. We don’t know what’s next in the government’s efforts to control drug costs, but we know that “doing nothing” is not an option for pharmaceutical manufacturers. The debate will undoubtedly continue on drug pricing and transparency, and it’s a matter of time before new regulatory measures are imposed greatly impacting all industry players, the way we do business, and ultimately our top line revenue performance.
Listen to the industry experts as they discuss what’s on the regulatory horizon in the march toward price transparency. Stay current on the latest industry developments and learn realistic actions you can take to be better prepared for what’s to come.